Pictet Asset Management Holding SA Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Pictet Asset Management Holding SA cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 108,008 shares of the medical equipment provider’s stock after selling 7,903 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Zimmer Biomet were worth $9,712,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ZBH. Key Financial Inc raised its stake in Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its stake in shares of Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares during the period. Root Financial Partners LLC purchased a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $31,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at approximately $32,000. Finally, Mather Group LLC. purchased a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $36,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This represents a 20.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.28% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research analyst reports. UBS Group reissued a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Stifel Nicolaus reduced their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research note on Wednesday. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research note on Wednesday. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Finally, William Blair initiated coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $102.43.

Zimmer Biomet Price Performance

Shares of ZBH opened at $83.07 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.83 and a fifty-two week high of $108.29. The firm’s 50 day moving average price is $92.53 and its 200 day moving average price is $92.72. The company has a market cap of $16.08 billion, a P/E ratio of 21.58, a PEG ratio of 1.91 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.73 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the prior year, the firm earned $1.81 EPS. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.